Naber K G, Dette G A, Kees F, Knothe H, Grobecker H
J Antimicrob Chemother. 1986 Apr;17(4):517-27. doi: 10.1093/jac/17.4.517.
The minimal inhibitory concentrations (MICs) of aztreonam and cefotaxime were determined against 400 isolates from urological in-patients with complicated and/or hospital acquired urinary tract infections (UTI). Against the Gram-negative rods the activities of both antibiotics were comparable except for higher activity of aztreonam against Pseudomonas aeruginosa. The pharmacokinetic study in nine elderly patients showed a prolonged plasma half life of aztreonam (2.7 h) as compared to younger volunteers (1.6-1.9 h). In a prospective randomized study 39 urological patients with complicated and/or hospital acquired UTI were treated with 1 g aztreonam or cefotaxime iv twice daily for 4 to 15 days. Cure was obtained in 5 out of 18 patients in the aztreonam and 7 out of 20 patients in the cefotaxime group. There were 3 superinfections, 7 relapses and 3 reinfections in the aztreonam group and 1 failure, 1 superinfection, 6 relapses and 5 reinfections in the cefotaxime group. There was no significant difference in therapeutic efficacy between the two antibiotics. Both antibiotics were tolerated well and seem to be equally effective in the treatment of complicated UTI caused by sensitive organisms.
测定了氨曲南和头孢噻肟对400株来自患有复杂性和/或医院获得性尿路感染（UTI）的泌尿外科住院患者的分离菌的最低抑菌浓度（MIC）。对于革兰氏阴性杆菌，除氨曲南对铜绿假单胞菌的活性较高外，两种抗生素的活性相当。在9名老年患者中进行的药代动力学研究显示，与年轻志愿者（1.6 - 1.9小时）相比，氨曲南的血浆半衰期延长（2.7小时）。在一项前瞻性随机研究中，39名患有复杂性和/或医院获得性UTI的泌尿外科患者接受了每日两次静脉注射1g氨曲南或头孢噻肟治疗4至15天。氨曲南组18名患者中有5名治愈，头孢噻肟组20名患者中有7名治愈。氨曲南组有3例二重感染、7例复发和3例再感染，头孢噻肟组有1例治疗失败、1例二重感染、6例复发和5例再感染。两种抗生素的治疗效果无显著差异。两种抗生素耐受性良好，在治疗由敏感菌引起的复杂性UTI方面似乎同样有效。
